‘Can-Fite’ Announces Positive Results In Eye Inflammation Drug Trial

CanFite - News Flash - IsraelIsraeli biopharmaceutical company Can-Fite BioPharma announced successful results in the preclinical trial of CF101 – a drug for the treatment of inflammations of the uvea, which is the middle layer of the eye. Such inflammations can result in blindness and according to the company are the fifth or sixth leading causes of blindness in the US.